⌘K

Home/Filings/4/0001578563-25-000173

4//SEC Filing

BAYER AKTIENGESELLSCHAFT 4

Accession 0001578563-25-000173

CIK 0001854270other

View on SEC.gov Company Profile

Filed

Mar 11, 8:00 PM ET

Accepted

Mar 12, 8:31 PM ET

Size

14.8 KB

Accession

0001578563-25-000173

Insider Transaction Report

Form 4

Period: 2025-03-10

Senti Biosciences, Inc.SNTI

Bayer World Investments B.V.

10% Owner

Transactions

Conversion
Series A Convertible Preferred Stock
2025-03-10−2,222→ 0 total
From: 2025-03-10→ Common Stock (2,222,000 underlying)
Conversion
Common Stock
2025-03-10+2,222,000→ 2,809,848 total

Holdings

Warrant
Exercise: $2.30From: 2025-03-10Exp: 2029-12-09→ Common Stock (3,333,000 underlying)
3,330,000

BAYER AKTIENGESELLSCHAFT

10% Owner

Transactions

Conversion
Common Stock
2025-03-10+2,222,000→ 2,809,848 total
Conversion
Series A Convertible Preferred Stock
2025-03-10−2,222→ 0 total
From: 2025-03-10→ Common Stock (2,222,000 underlying)

Holdings

Warrant
Exercise: $2.30From: 2025-03-10Exp: 2029-12-09→ Common Stock (3,333,000 underlying)
3,330,000

BAYER HEALTHCARE LLC

10% Owner

Transactions

Conversion
Series A Convertible Preferred Stock
2025-03-10−2,222→ 0 total
From: 2025-03-10→ Common Stock (2,222,000 underlying)
Conversion
Common Stock
2025-03-10+2,222,000→ 2,809,848 total

Holdings

Warrant
Exercise: $2.30From: 2025-03-10Exp: 2029-12-09→ Common Stock (3,333,000 underlying)
3,330,000

Bayer US Holding LP

10% Owner

Transactions

Conversion
Common Stock
2025-03-10+2,222,000→ 2,809,848 total
Conversion
Series A Convertible Preferred Stock
2025-03-10−2,222→ 0 total
From: 2025-03-10→ Common Stock (2,222,000 underlying)

Holdings

Warrant
Exercise: $2.30From: 2025-03-10Exp: 2029-12-09→ Common Stock (3,333,000 underlying)
3,330,000

Footnotes (3)

[F1]Each share of Series A Convertible Preferred Stock ("Series A") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025.
[F2]The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.
[F3]The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased.

Documents

1 file

4
primary_doc.xmlPrimary
PRIMARY DOCUMENT

Issuer

Senti Biosciences, Inc.

CIK 0001854270

Entity typeother

Related Parties

1

filerCIK 0001144145

Filing Metadata

Form type: 4
Filed: Mar 11, 8:00 PM ET
Accepted: Mar 12, 8:31 PM ET
Size: 14.8 KB

View on SEC.gov